Patent · US Active

PD-1/Pd-L1 inhibitors

US12338233B2 · kind B2 · utility

0Cited by

7References

4Claims

0Family size

Assignee

Gilead Sciences, Inc. · US

Inventors

Evangelos Aktoudianakis · Redwood City, US
Aesop Cho · Mountain View, US
Zhimin Du · Belmont, US
Michael Graupe · Pacifica, US
Lateshkumar Thakorlal Lad · Belmont, US
Paulo A. Machicao Tello · San Mateo, US
Jonathan William Medley · San Mateo, US
Samuel E. Metobo · Foster City, US
Prasenjit Kumar Mukherjee · South San Francisco, US
Devan Naduthambi · San Bruno, US
Eric Q. Parkhill · San Francisco, US
Barton W. Phillips · San Mateo, US
Scott Preston Simonovich · Oakland, US
Neil H. Squires · San Francisco, US
Peiyuan Wang · San Mateo, US
William J. Watkins · Saratoga, US
Jie Xu · Foster City, US
Kin S. Yang · Foster City, US
Christopher Allen Ziebenhaus · San Francisco, US

Key dates

Filing date	Dec 1, 2022
Grant date	Jun 24, 2025
Priority date	—
Expiry date	Dec 1, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K16/2827
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.